Latest Mesoblast News & Updates

See the latest news and media coverage for Mesoblast. We track all announcements, press releases, and industry mentions in real time, all in one place.

Mesoblast

Commercial-stage biotechnology company developing allogeneic cell therapies

mesoblast.com

Headquarters: Melbourne, Australia
Founded year: 2004
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Mesoblast

In short: Mesoblast reported $115 million in first-year Ryoncil revenue, narrowed its fiscal 2026 loss, and completed Phase 3 back pain dosing.

Company announcements

August 24 Mesoblast

Mesoblast reports strong FY2026 revenue growth and pipeline advancements

Total revenue reached US$120.3 million from the US commercial launch of RYONCIL. The company also completed patient treatment in its Phase 3 back pain trial.

August 16 Mesoblast

Mesoblast completes treatment phase in P3 trial for chronic lower back pain

The biopharmaceutical company reached a major milestone by completing patient treatments in its Phase 3 clinical trial targeting chronic lower back pain.

August 13 Mesoblast

Mesoblast announces becoming a substantial holder

A shareholder acquired 3.8% voting power, triggering disclosure obligations under Australian law. The notice was filed August 13, 2026.

August 3 Mesoblast

Mesoblast reports ceasing to be a substantial holder

The company has filed a notice with the ASX detailing the change in shareholding.

Media coverage

September 2 The Globe and Mail

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of...

Never miss news about Mesoblast

Track Mesoblast and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Mesoblast competitors & trending companies

Browse news for competitors to Mesoblast and other trending companies.